BRIEF published on 12/03/2024 at 14:34, 1 year 11 months ago Eckert & Ziegler annonce des changements au sein de son conseil d'administration et de son conseil de surveillance Eckert & Ziegler Conseil De Surveillance Conseil Exécutif Jutta Ludwig Dr Gunnar Mann
PRESS RELEASE published on 12/03/2024 at 14:29, 1 year 11 months ago Eckert & Ziegler: Changes in the Executive Board and Supervisory Board Eckert & Ziegler SE appoints Dr. Gunnar Mann to Executive Board and welcomes changes in Supervisory Board. Dr. Mann to lead Medical segment Executive Board Supervisory Board Eckert & Ziegler SE Medical Segment Dr. Gunnar Mann
BRIEF published on 12/02/2024 at 09:05, 1 year 11 months ago Eckert & Ziegler Initiates Actinium-225 Production to Tackle Global Shortage Nuclear Medicine Radiopharmaceuticals Actinium-225 Production Isotope Supply GMP Certification
BRIEF published on 12/02/2024 at 09:05, 1 year 11 months ago Eckert & Ziegler lance la production d'actinium 225 pour faire face à la pénurie mondiale Produits Radiopharmaceutiques Médecine Nucléaire Production D'actinium 225 Approvisionnement En Isotopes Certification GMP
PRESS RELEASE published on 12/02/2024 at 09:00, 1 year 11 months ago Eckert & Ziegler Begins Production of Actinium-225, Paving the Way for GMP-Grade Supply Eckert & Ziegler starts Actinium-225 production in collaboration with Czech Academy of Sciences, aiming for GMP-grade supply to boost alpha-emitting radiopharmaceuticals development Eckert & Ziegler Production Radiopharmaceuticals Actinium-225 GMP-grade
BRIEF published on 11/27/2024 at 09:05, 1 year 11 months ago Eckert & Ziegler Gains European Approval for Theralugand® Cancer Therapy Radiopharmaceuticals Lutetium-177 European Approval Theralugand®
BRIEF published on 11/27/2024 at 09:05, 1 year 11 months ago Eckert & Ziegler obtient l'approbation européenne pour Theralugand® Produits Radiopharmaceutiques Thérapie Contre Le Cancer Lutetium-177 Theralugand® Agrément Européen
PRESS RELEASE published on 11/27/2024 at 09:00, 1 year 11 months ago Eckert & Ziegler Achieves European Approval for Theralugand® - Lutetium-177 Chloride (n.c.a) Eckert & Ziegler receives EC approval for Theralugand® - Lutetium-177 Chloride, expanding cancer therapy options in Europe Eckert & Ziegler Cancer Therapy EC Approval Theralugand Lutetium-177 Chloride
BRIEF published on 11/22/2024 at 15:32, 1 year 11 months ago Eckert & Ziegler Increases 2024 Financial Forecast Eckert & Ziegler Sales Increase Financial Forecast EBIT Growth 2024 Business
BRIEF published on 11/22/2024 at 15:32, 1 year 11 months ago Eckert & Ziegler augmente ses prévisions financières pour 2024 Eckert & Ziegler Prévisions Financières Augmentation Des Ventes Croissance Du Résultat D'exploitation (EBIT) Entreprise 2024
Published on 11/11/2026 at 03:30, 5 hours 34 minutes ago CoTec Holdings Corp. Files Third Quarter Financial Statements and MD&A and Provides Market Commentary
Published on 11/11/2026 at 00:40, 8 hours 24 minutes ago Upgraded Tunkillia MRE Validates Optimised Scoping Study
Published on 11/10/2026 at 23:30, 9 hours 34 minutes ago CCL Industries Announces 2026 Third Quarter Results
Published on 11/10/2026 at 23:00, 10 hours 4 minutes ago Vanta Announces Appointment of Chief Financial Officer and Corporate Secretary
Published on 11/10/2026 at 23:00, 10 hours 4 minutes ago Battery X Metals Announces Appointment of Chief Financial Officer and Corporate Secretary
Published on 11/11/2026 at 08:31, 33 minutes ago Delivery Hero SE: Notice to the Bondholders of the EUR 500 million Convertible Bonds due 2029 (ISIN DE000A3MP437 – Common Code 238511097 – German Securities Code (WKN) A3MP43)
Published on 11/11/2026 at 08:30, 34 minutes ago Delivery Hero SE: Notice to the Bondholders of the EUR 1,000 million Convertible Bonds due 2030 (ISIN DE000A30V5R1 – Common Code 258943848 – German Securities Code (WKN) A30V5R)
Published on 11/11/2026 at 08:30, 34 minutes ago Delivery Hero SE: Notice to the Bondholders of the EUR 750 million Convertible Bonds due 2028 (ISIN DE000A3H2WQ0 – Common Code 220637387 – German Securities Code (WKN) A3H2WQ)
Published on 11/11/2026 at 08:30, 34 minutes ago aap Implantate AG: Management Board refines 2026 forecast and provides first outlook for 2027 – Ambition 2030: Revenue of at least EUR 21 million with an EBITDA margin of 17.5% to 22.5%
Published on 11/10/2026 at 18:00, 15 hours 4 minutes ago Déclaration du nombre total des droits de vote et du nombre d’actions au 31 octobre 2026
Published on 11/10/2026 at 17:45, 15 hours 19 minutes ago Damartex / Descriptif du programme de rachat d'actions
Published on 11/10/2026 at 17:35, 15 hours 29 minutes ago ENGIE - Déclaration du nombre total d'actions et de droits de vote au 31 octobre 2026
Published on 11/10/2026 at 17:31, 15 hours 33 minutes ago CNP Assurances SA annonce le succès de l’émission d’une obligation subordonnée Tier 2 de 500 M€.
